Surrogate endpoints in clinical trials: definition and operational criteria.

By R. Prentice. 1989

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

The State of Applied Econometrics - Causality and Policy Evaluation (2016, neutral): “Regression Discontinuity Designs have a long history, going back to work in psychology in the fifties by Thistlewaite and Campbell [1960], but the methods did not become part of the mainstream economics literature until the early 2000s (with Goldberger [1972, 2008] an exception).”
Latent class instrumental variables: A clinical and biostatistical perspective (2015, background): “The standard assumption underlying this extrapolation is the well-known Prentice Criterion, namely, the effect of treatment on true endpoint occurs only through the surrogate endpoint [64].”
Principal Stratification in Causal Inference (2002, methodology): “(Prentice, 1989, used a hazard regression parameterization for multiple-time measurements on P E Q V R T S .”
Principal causal effect identification and surrogate end point evaluation by multiple trials (2015, background): “Prentice (1989) first proposed the statistical surrogate criterion, which requires conditional independence of the treatment and the observed end point given the observed surrogate.”
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework (2001, background): “26 the most stringent of which requires a valid surrogate endpoint to account for all of the effects of the intervention on the clinical endpoint”
Some Thoughts Concerning Transfer Learning, with Applications to Meta-analysis and Data-sharing Estimation (2012, unknown): “Putting aside debates on whether good prediction, void of causal mediation is suﬃcient for the task (see Prentice, 1989; Joﬀe and Green, 2009; Pearl and Bareinboim, 2011; Pearl, 2011), the problem ﬁts well into the model of Figs.”
Related Causal Frameworks for Surrogate Outcomes (2009, methodology): “This article relates these two paradigms to each other and to four approaches proposed for defining surrogacy: (1) Prentice’s original definition (Prentice, 1989); (2) a definition in terms of direct and indirect effects of the treatment (Taylor, Wang, and Thiebaut, 2005); (3) a meta-analytic defini”
Semiparametric regression estimation in the presence of dependent censoring (1995, background): “The Wj are often referred to as surrogates for Y (Prentice, 1989; Pepe, 1992).”
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury* (2005, methodology): “A surrogate end point analysis (24) was used to determine whether plasma IL-6 measurement on day 3 is a valid surrogate marker for the beneficial effects of the 6 mL/kg ventilator group on mortality, adjusting for baseline IL-6 level.”
On the use of surrogate end points in randomized trials (2000, background): “Since the publication of Prentice (1989) de®ning the Prentice criterion, this criterion has come to dominate the terms of the debate between statisticians on the use of surrogate end points.”
The Life-Cycle Benefits of an Influential Early Childhood Program (2016, unknown): “These methods are related to the older “surrogate marker” literature in biostatistics (see e.g., Prentice, 1989).”
Long-term Causal Inference Under Persistent Confounding via Data Combination (2022, background): “Examples include the statistical surrogate criterion [Prentice, 1989], principal surrogate criterion [Frangakis and Rubin, 2002], consistent surrogate criterion [Chen et al.”
Random Effects Models for Longitudinal Data (2010, background): “The first formal single trial approach to validate markers is due to Prentice (1989), who gave a definition of the concept of a surrogate endpoint, followed by a series of operational criteria.”